Processa Pharmaceuticals, INC 8-K filings

Processa Pharmaceuticals, Inc. announced the outcomes of its 2026 Annual Meeting of Shareholders, where key proposals including an amendment to the 2019 Omnibus Incentive Plan and the ratification of its independent auditor were approved.

Processa Pharmaceuticals has acquired Vidya Therapeutics and secured approximately $200 million in a private placement to advance Vidya's lead asset, VT-7208, through key clinical milestones.

Dr. Sian Bigora, Chief Development and Regulatory Officer, will transition to a part-time role effective May 1, 2026.

Processa Pharmaceuticals, Inc. announced it has regained compliance with NASDAQ's minimum bid price requirement, closing the matter.

Processa Pharmaceuticals, Inc. has filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of its common stock, effective December 16, 2025.

Processa Pharmaceuticals shareholders approved increasing authorized common stock, a reverse stock split, and an expanded incentive plan.

Processa Pharmaceuticals shareholders approved proposals to increase authorized shares, effect a reverse stock split, and expand its incentive plan.

Processa Pharmaceuticals, Inc. announced the reconvening of its Special Shareholder Meeting on September 11, 2025, after an earlier adjournment.

Processa Pharmaceuticals, Inc. adjourned its Special Shareholder Meeting due to a lack of quorum, rescheduling it for September 12, 2025.

Processa Pharmaceuticals, Inc. announced a change in the physical location for its upcoming 2025 Special Meeting of Stockholders.

Processa Pharmaceuticals secured a $1.3 million private placement and announced plans to evaluate corporate cryptocurrency treasury strategies to diversify capital and enhance financial flexibility.

Processa Pharmaceuticals, Inc. received a second 180-day extension from Nasdaq to regain compliance with the minimum $1.00 bid price requirement, with a potential reverse stock split planned.

Processa Pharmaceuticals, Inc. announced a $1.3 million private placement of common stock and is evaluating corporate cryptocurrency treasury strategies to diversify its capital base.

Processa Pharmaceuticals, Inc. has filed a prospectus supplement enabling the sale of up to $5,239,073 of common stock through an at-the-market equity distribution agreement.

Processa Pharmaceuticals, Inc. announced that its shareholders approved the election of all six directors, the issuance of common stock for warrants, the appointment of Cherry Bekaert, LLP as independent auditor, and executive compensation at its 2025 Annual Meeting.

Processa Pharmaceuticals, Inc. has reconvened its Annual Shareholder Meeting for July 18, 2025, after an initial adjournment on June 30, 2025, due to a lack of quorum, which has now been achieved through proxies.

Processa Pharmaceuticals, Inc. has announced a significant strategic portfolio review and pipeline realignment, including a $7 million capital infusion and a major licensing option deal, to enhance shareholder value and focus on high-potential oncology assets.

Processa Pharmaceuticals, Inc. announced an amendment to its agreement with Yuhan Corporation and the adjournment of its Annual Shareholder Meeting due to a lack of quorum, rescheduling it for July 30, 2025.

Processa Pharmaceuticals, Inc. announced the pricing and closing of a public offering raising approximately $6.3 million, intended to fund its Phase 2 clinical trial for NGC-Cap and for general corporate purposes.

Processa Pharmaceuticals, Inc. has entered into a binding term sheet granting Intact Therapeutics an exclusive option to license its Phase 2B-ready drug candidate, PCS12852, for diabetic gastroparesis, with potential payments totaling up to $452.5 million.

Processa Pharmaceuticals publishes an investor presentation on its website, outlining its current status and future plans.

Processa Pharmaceuticals received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Processa Pharmaceuticals successfully prices and closes a $5 million public offering to fund general corporate purposes.

Processa Pharmaceuticals has changed its independent auditor from BD & Company to Cherry Bekaert LLP following BD & Company's merger with Citrin Cooperman.

Processa Pharmaceuticals has announced the dosing of the first patient in a Phase 2 clinical trial for NGC-Cap, a drug aimed at treating metastatic breast cancer.

Processa Pharmaceuticals announced progress in its drug development pipeline, including the initiation of a Phase 2 trial for NGC-Cap in breast cancer, and reported its financial results for the second quarter of 2024.

Processa Pharmaceuticals has announced FDA clearance for its Investigational New Drug (IND) application for NGC-Cap, paving the way for a Phase 2 clinical trial in breast cancer patients.

Processa Pharmaceuticals has appointed Russell Skibsted as its new Chief Financial Officer, effective July 16, 2024, succeeding James Stanker who is retiring.

Processa Pharmaceuticals held its 2024 Annual Meeting, electing six directors, approving an increase in shares for its incentive plan, ratifying its accounting firm, and approving executive compensation.

Processa Pharmaceuticals has entered into a sales agreement to potentially sell up to $2.4 million of its common stock through an at-the-market offering.